BioVie Inc (NASDAQ:BIVI) CEO Cuong Do joined Steve Darling from Proactive to share news the Company’s Phase 2 trial for NE3107’s potential pro-motoric impact in Parkinson’s disease has fully enrolled 44 patients. Cuong telling Proactive the company is expecting initial data in December. This study, which is la double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinson's disease, has 44 patients being treated with NE3107 or a placebo.
BioVie Pharma Inc announces NE3107 Phase 2 trial has been fully enrolled
